Mineralys Therapeutics Inc

MLYS remains in a Stage 2 advancing corrective reset with persistent higher highs and lows and rising intermediate EMAs, supporting a Bullish medium-term bias. However, price is extended far above the 9/21/50 EMA envelope and is marked by overbought RSI and extreme Options Score, making immediate entry unfavorable. We will Stalk, seeking pullbacks into the rising 9/21 EMA support zone for potential buy opportunities via pullback interaction.

• ↑9.1 mmHg mean systolic reduction in LAUNCH-HTN/ADVANCE-HTN trials.
• ↑$646 M cash on hand funds development and launch through 2028.
• ↓Q1 2026 net loss of $39.3 M and rising G&A costs ($21 M) pressure margins.